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Abstract. Background/Aim: Anthracimycin, a secondary
metabolite of Streptomyces, has been shown to inhibit the
invasion of certain cancer cell lines. Materials and Methods:
In this study we evaluated the effect of anthracimycin on cell
growth and signaling pathways in hepatocellular carcinoma
(HCC). Results: Anthracimycin suppressed cell proliferation
and motility and induced apoptosis in human HCC cell lines.
Furthermore, anthracimycin had no effect on the enrichment
of EpCAM-high liver cancer stem cells (CSCs), while
fluorouracil dramatically enriched the CSCs with activation
of the stemness-related genes EPCAM and SOX9 in HuH7
cells. Mechanistically, anthracimycin suppressed mammalian
target of rapamycin (mTOR) signaling, and was most
effective at inhibiting HCC cell proliferation with mTOR
activation. Conclusion: Anthracimycin is a novel mTOR
inhibitor capable of suppressing the proliferation of CSCs
and non-CSCs equally well in HCC, and it is suggested that
anthracimycin could be effective in the eradication of HCC
associated with mTOR-signaling activation.
Hepatocellular carcinoma (HCC) is the fifth most common
cancer and the second leading cause of cancer-related death
in men worldwide (1). Sorafenib tosylate is a multikinase
inhibitor reported to prolong overall survival (by a median
of ~3 months) in advanced HCC patients; however, its
response rate is generally <5% according to evaluation
criteria defined by the Response Evaluation Criteria in Solid
Tumors (2, 3), indicating that more effective reagents are
required for the treatment of advanced HCCs. Recent
evidence suggested that some HCCs are hierarchically
organized with a subset of cells called cancer stem cells
(CSCs) that possess stem cell features (4). CSCs show
chemoresistance to cytotoxic reagents and, therefore, are
considered critical targets for HCC eradication (5-7). 
Anthracimycin, previously designated as TPU-0114, is a
novel polyketide compound with a molecular weight of 396 Da
(C25H32O4) (Figure 1A) (5-7). This structurally unique
compound is produced by an actinomycete strain belonging to
the genus Streptomyces isolated from a compost sample. This
small molecule potentially inhibits the invasion of some cancer
cell lines (5), but it remains unclear how the compound affects
cancer cell growth and motility. In this study, we evaluated the
effect of anthracimycin on cell growth, motility, activated
signaling pathways, and stemness in HCC.
Materials and Methods
Cell lines and reagents. Huh1, Huh7, and SK-Hep-1 cells were
routinely cultured with Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). Three
hepatocellular carcinoma cell lines established from primary HCC
samples were also routinely cultured with DMEM supplemented
with 10% FBS, as previously described (8). Anthracimycin was
purified from Streptomyces strain NITE P-769 as described
previously (5). Fluorouracil (5-FU) was purchased from Taiho
Pharmaceutical (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan).
Cell proliferation and apoptosis. Briefly, 2×103 cells were seeded in
96-well plates, and cell proliferation was evaluated in quadruplicate
using the Cell-counting Kit 8 (Dojindo Laboratories, Kumamoto,
Japan). Anthracimycin was dissolved in dimethyl sulfoxide (DMSO),
and cells were treated with 0.1% DMSO (control) or the indicated
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concentration of anthracimycin for 72 h. The IC50 in each cell line was
calculated by the GraphPad PRISM software version 5.0.4 (GraphPad
Software, San Diego, CA, USA). Annexin V-positive apoptotic cells
were evaluated by immunofluorescence using an ANNEXIN V-FITC
Fluorescence Microscopy Kit (BD Biosciences, San Jose, CA, USA)
according to manufacturer instructions. Briefly, 1×105 cells were
seeded in a 2-well chamber slide and treated with 0.1% DMSO
(control), 2.5 μg/mL 5-FU, or 2.5 μg/ml anthracimycin for 48 h.
Membranous staining of annexin V-positive cells was evaluated by a
BZ-9000 fluorescence microscope (Keyence Corp., Tokyo, Japan). The
number of annexin V-positive cells per 100 cells (evaluated by 4',6-
diamidino-2-phenylindole positivity) was measured in quadruplicate.
Wound-healing assay. A wound-healing assay was performed using
μ-Slide 8-well chambers and culture inserts (Ibidi, Martinsried,
Germany) as described previously (9). Briefly, 1×106 HuH7 cells
were labeled with DiO for 20 min and washed with phosphate-
buffered saline (PBS). Cells (2×103 cells/50 μL/well) were then
incubated in a culture insert in μ-Slide 8-well chambers overnight.
Silicone inserts were removed, and the culture media was
immediately replaced with DMEM containing 10% FBS and 0.1%
DMSO (control) or 2.5 μg/ml anthracimycin. Time-lapse image
analysis was performed for 48 h using a CSU-X1 spinning-disk
confocal microscope (Yokogawa, Tokyo, Japan) and an Andor iXon3
EMCCD camera system (Andor Technology, Belfast, UK) (8).
Fluorescence-activated cell sorting (FACS) analysis. FACS analysis
was performed to evaluate the expression status of the CSC marker
EpCAM. Briefly, 2×105 HuH7 cells were seeded in 6-well plates
and cultured overnight. Cells were then cultured with DMEM
supplemented with 10% FBS and 0.1% DMSO (control), 2.5 μg/ml
5-FU, or 2.5 μg/mL anthracimycin for 72 h. Cells were trypsinized,
washed, and resuspended in Hank’s Balanced Salt Solution (Lonza,
Basel, Switzerland) supplemented with 1% 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid and 2% FBS. Cells were then
incubated with the fluorescein isothiocyanate (FITC)-conjugated
anti-EpCAM monoclonal antibody Clone Ber-EP4 (Dako Japan,
Tokyo, Japan) on ice for 30 min and analyzed using a FACSCalibur
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Figure 1. Effect of anthracimycin on cancer cell proliferation, apoptosis, and motility. (A) Structural formula of anthracimycin. (B) Anthracimycin
suppressed proliferation of HuH1, HuH7, and SK-Hep-1 HCC cell lines in a dose-dependent manner. (C) Anthracimycin treatment (2.5 µg/ml for
48 h) induced annexin V-positive apoptotic cells compared to the control (0.1% DMSO). (D) Wound-healing assay results showed that anthracimycin
(2.5 µg/ml) inhibited cell motility in HuH7 cells.
(BD Biosciences) (10). The FlowJo software version 7.6.5 (FlowJo,
LLC, Ashland, OR, USA) was used to analyze the EpCAM-high
cell population for each experimental condition.
Quantitative reverse transcription-polymerase chain reaction (qRT-
PCR). Total RNA was extracted using TRIzol (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. Expression
of EPCAM and SOX9 was determined in triplicate using the 7900
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). Each sample was normalized relative to 18S ribosomal RNA
expression. Probes used were: EPCAM, Hs00158980_m1, SOX9,
Hs00165814_m1, and 18S, Hs99999901_s1 (Applied Biosystems). 
Western blot. Briefly, 2×105 cells were seeded in 6-well plates and
cultured overnight. Cells were then cultured with DMEM
supplemented with 10% FBS and 0.1% DMSO (control), 5-FU,
or anthracimycin at the indicated concentrations and for the
indicated time. Adherent cells were washed with PBS, and whole-
cell lysates were prepared using radioimmunoprecipitation assay
lysis buffer. Mouse monoclonal antibody to human p21Waf1/Cip1
clone DCS60, rabbit monoclonal antibody to human phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) clone D13.14.4E, rabbit
monoclonal antibody to human Bcl-xL clone 54H6, rabbit
monoclonal antibody to human mTOR clone 7C10, rabbit
monoclonal antibody to human Raptor clone 24C12, and rabbit
polyclonal antibodies to human p16 INK4A, NF-ĸB p65,
phospho-NF-ĸB p65 (Ser468), Akt, phospho-Akt (Thr308),
p44/42 MAPK (Erk1/2), Rheb, phospho-mTOR (Ser2448), p70
S6 Kinase, phospho-p70 S6 Kinase (Thr389), and β-actin were
obtained from Cell Signaling Technology (Danvers, MA, USA)
and diluted according to the protocol recommended for each
antibody. Immune complexes were visualized by enhanced
chemiluminescence (Amersham Biosciences Corp., Piscataway,
NJ, USA), and mTOR protein concentrations detected by western
blot bands were quantified using ImageJ software version 1.46r
(National Institutes of Health, Bethesda, MD, USA). 
Hayashi et al: Anthracimycin; A mTOR Inhibitor for Hepatocellular Carcinoma
3399
Figure 2. The effect of anthracimycin on liver cancer stemness. (A) FACS analysis of cancer stem cell marker EpCAM expression in HuH7 cells
treated with 5-FU (2.5 µg/ml for 72 h; left panel) or anthracimycin (2.5 µg/ml for 72 h; right panel). (B) qRT-PCR analysis of EPCAM and SOX9
in HuH7 cells treated with 5-FU or anthracimycin at the indicated concentrations for 72 h.
Statistical analysis. Student t-tests were performed using GraphPad
Prism software version 5.0.4 (GraphPad Software) to compare the
test groups evaluated by immunofluorescence and qRT-PCR.
Correlation between the IC50 of anthracimycin and mTOR
concentration was also examined by the Pearson correlation
coefficient using GraphPad Prism software (GraphPad Software).
Results
Anthracimycin suppressed cell proliferation and motility and
induced apoptosis in human HCC. We evaluated the effect of
anthracimycin on cell proliferation in three representative
human HCC cell lines (HuH1, HuH7, and SK-Hep-1).
Anthracimycin suppressed cell proliferation in all cell lines in
a dose-dependent manner (Figure 1B), with the IC50 in HuH1,
HuH7, and SK-Hep-1 cells measured at 2.5 μg/ml, 2.8 μg/ml,
and 3.0 μg/ml, respectively. We also measured the number of
annexin V-positive cells treated with 0.1% DMSO (Control),
2.5 μg/ml 5-FU, and 2.5 μg/ml anthracimycin and identified
a dramatic and statistically significant increase in annexin V-
positive cells treated with anthracimycin (Figure 1C).
Additionally, evaluation of the effect of anthracimycin on cell
motility by wound-healing assay revealed that 2.5 μg/ml
anthracimycin strongly suppressed HuH7 motility (Figure 1D). 
Anthracimycin suppressed cell proliferation without
enrichment of liver CSCs in HCC. CSCs are considered
resistant to cytotoxic reagents and, therefore, the CSC
population is generally enriched following treatment.
Consistently, when HuH7 cells were treated with 2.5 μg/ml
5-FU for 72 h, EpCAM-high liver CSCs were dramatically
enriched (60.2%) as compared with the control (24.4%)
(Figure 2A, left panel), suggesting that EpCAM-high liver
CSCs were resistant to 5-FU treatment. Interestingly,
anthracimycin treatment did not enrich EpCAM-high liver
CSCs (31.6%) (Figure 2A, right panel). Additionally,
although 5-FU treatment resulted in significant up-regulation
of genes encoding the CSC markers EPCAM and SOX9,
anthracimycin treatment did not induce similar upregulation
of stemness-related genes in a dose-dependent manner
according to qRT-PCR analysis (Figure 2B). 
We investigated the effect of anthracimycin treatment on
cell-cycle arrest using SK-Hep-1 cells lacking p53 mutations,
making them susceptible to cytotoxic reagents via the p53-
p21 pathway. Consistently, 5-FU treatment strongly induced
p21 expression in a dose-dependent manner in SK-Hep-1
cells. However, anthracimycin treatment had no effect on
p21 induction, suggesting that anthracimycin suppressed cell
proliferation and induced apoptosis in a p53-independent
manner (Figure 3A). We further evaluated the effect of
anthracimycin treatment on NF-ĸB, Akt, and ERK signaling
in HuH7 cells by western blot (Figure 3B). Adherent HuH7
cells treated with anthracimycin for 72 h showed induction
of phospho-NF-ĸB (p65) and phospho-Akt as compared with
control or 5-FU-treated HuH7 cells. Anthracimycin treatment
had no effect on phospho-ERK1/2 proteins, but resulted in a
slight decrease in the concentration of anti-apoptosis protein
Bcl-xl relative to levels observed in the control or 5-FU-
treated HuH7 cells. These data suggested that anthracimycin
treatment may block signaling pathways downstream of Akt-
or NF-ĸB-signaling cascades, resulting in a positive-
feedback mechanism to compensate for the inhibited
signaling pathways, which might result in Akt or NF-ĸB
phosphorylation in adherent anthracimycin-treated cells. 
Anthracimycin suppressed mTOR signaling and HCC cell
proliferation in an mTOR concentration-dependent manner.
To determine the potential molecular targets inhibited by
anthracimycin treatment, we first screened 118 kinases
activated in cancer using Life Technologies SelectScreen
Profiling Service. We found that anthracimycin inhibited
PIK3CA/PIK3R1 expression [p110α/p85α phosphoinositide
(PI)-3 kinase] by 46% in vitro at anthracimycin
concentrations of 20 μM (~8 μg/ml) as examined by the
Adapta universal kinase assay (Life Technologies). However,
the IC50 in HuH1, HuH7, and SK-Hep-1 cells was ~3 μg/ml
(Figure 1A), and Akt exhibited enhanced levels of
phosphorylation in anthracimycin-treated HuH7 cells (Figure
3B). Therefore, we considered that PI-3 kinase was an
unlikely direct molecular target of anthracimycin. We next
evaluated the mTOR-signaling pathway, because mTOR is a
downstream target activated by PI-3 kinase-Akt signaling,
and downstream molecules associated with Akt signaling
may be directly inhibited by anthracimycin according to
western blot data (Figure 3B). Interestingly, when we treated
HuH7 cells with 5-FU or anthracimycin for 8 h, we
identified a dramatic, dose-dependent reduction in phospho-
p70 S6 kinase protein following anthracimycin treatment
(Figure 4A). This effect was not observed following 5-FU
treatment. Since expression of Rheb, mTOR, phospho-
mTOR, Raptor, and p70 S6 kinase was not affected by
anthracimycin treatment, this implied that anthracimycin did
not specifically target PI-3 kinase in vitro as suggested by
the SelectScreen Profiling Service. Rather, these data
suggested that anthracimycin might inhibit formation of
mTOR complex 1 (mTORC1), thereby inhibiting
phosphorylation of p70 S6 kinase. A similar observation was
reported involving the mTOR-signaling inhibitor rapamycin,
which was discovered in the bacterium Streptomyces
hygroscopius. We evaluated the concentrations of mTOR and
phospho-mTOR in three representative HCC cell lines
(HuH1, HuH7, and SK-Hep-1) and three HCC cell lines
established from primary HCCs (HCC 1, HCC 2, and HCC
3). The concentrations of mTOR and phospho-mTOR were
heterogeneous in each primary HCC cell line, while HuH1,
HuH7, and SK-Hep-1 cells exhibited increased activation of
mTOR signaling as compared with HCC 1, HCC 2, and
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HCC 3 cells (Figure 4B). Interestingly, the sensitivity of the
primary HCC cell lines to anthracimycin (IC50) negatively
correlated with mTOR concentration (p=0.0032, r=−0.9535)
(Figure 4C), suggesting that the effect of anthracimycin on
cell proliferation is dependent upon activation of the mTOR-
signaling pathway in HCC. Collectively, these data suggested
that anthracimycin suppressed HCC cell proliferation and
motility possibly through inhibition of the mTOR-signaling
pathway. Given that anthracimycin did not affect induction
of cancer stemness and was most effective in HCC cell lines
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Figure 3. The effect of anthracimycin on growth-signaling pathways. (A)
Western blot analysis of p21 and p16 in SK-Hep-1 cells treated with 5-FU
or anthracimycin at the indicated concentrations for 72 h. (B) Western blot
analysis of NF-ĸB-, Akt-, and ERK-signaling proteins in HuH7 cells
treated with 5-FU (2.5 µg/ml) or anthracimycin (2.5 µg/ml) for 72 h.
Figure 4. The effect of anthracimycin on the mTOR-signaling pathway.
(A) Western blot analysis of mTOR-signaling proteins in HuH7 cells
treated with 5-FU or anthracimycin at the indicated concentrations for
8 h. The black arrow indicates the observed dose-dependent decrease
in phosphorylated p70 S6 kinase protein following anthracimycin
treatment. (B) Western blot analysis of mTOR and phospho-mTOR
proteins in human HCC cell lines and HCC cells established from
primary HCC samples. (C) Scatter-plot analysis of mTOR concentration
and the IC50 of anthracimycin in HCC cells. A negative correlations
between mTOR concentration and anthracimycin IC50 was observed
(r=−0.9535, p=0.0032). Relative mTOR concentration was calculated
using ImageJ software and evaluated against the mTOR concentration
measured in primary HCC 3 cells.
exhibiting abundant mTOR expression, anthracimycin may
be a mTOR inhibitor valuable for treating HCC associated
with mTOR-signaling activation.
Discussion
Natural microbial products are an important resource for cancer
drug discovery and provide significant anticancer reagents,
including doxorubicin, mitomycin C, and rapamycin. Here, we
discovered that anthracimycin produced by Streptomyces strain
NITE P-769 inhibited HCC cell proliferation and motility and
induced apoptosis potentially through suppression of the
mTOR-signaling pathway. Given that previous findings
suggested that anthracimycin was less toxic to normal cells
relative to cancer cells (unpublished data), anthracimycin may
be a good candidate for the treatment of advanced HCCs
associated with mTOR-signaling activation.
TOR is a serine/threonine kinase highly conserved from
yeast to mammals that regulates cell growth, cell-cycle
progression, and metabolism (11). mTOR is a mammalian
target of rapamycin, which is a macrolide produced by S.
hygroscopicus, that belongs to the PI-3 kinase family and
interacts with several proteins to form two distinct protein
complexes (mTORC1 and mTORC2) that function as kinases
to phosphorylate p70 S6 kinase and 4E-BP1 (by mTORC1) or
Akt (by mTORC2). Rapamycin mainly inhibits mTORC1-
complex formation by binding to FK506-binding protein 12 to
suppress phosphorylation of p70 S6 kinase. Our data indicated
that anthracimycin inhibited the phosphorylation of p70 S6
kinase without directly affecting mTOR phosphorylation.
However, the mechanisms associated with anthracimycin
suppression of mTOR signaling remain unclear and should be
elucidated in future studies. 
Since mTOR plays a fundamental role in cell metabolism,
most growth factors activate mTOR signaling mainly
through activation of the Akt-signaling pathway. Stimulation
of mTOR signaling activates protein synthesis, lipid
synthesis, and energy metabolism, which are key metabolic
changes related to cancer growth (12, 13). Consequently,
mTOR signaling is activated in many types of cancer (14),
with its activation correlated with advanced tumor stages and
poor survival outcomes in various types of cancers, including
HCC (15). Furthermore, accumulating evidence suggested
that the PI-3 kinase/Akt/mTOR-signaling pathway may play
a crucial role in CSC maintenance (16). Inhibition of mTOR
signaling induced a paused pluripotent state in colon, lung,
pancreatic and leukemia CSCs (17-21). Our data indicated
that anthracimycin equally suppressed liver CSCs and non-
CSCs in HuH7 cells, suggesting that mTOR constitutes a
viable molecular target for the eradication of HCC CSCs.
Consistently, a recent paper indicated the close link between
the expression of cancer stem cell markers and the activation
of PTEN/AKT/mTOR pathway components in HCC (22).
The mTOR inhibitors temsirolimus and everolimus are
approved for the treatment of advanced renal cell carcinoma,
breast cancer, and pancreatic neuroendocrine tumors (23).
Sirolimus, temsirolimus, and everolimus are currently
evaluated for the treatment of advanced HCC as first- or
second-line therapeutics (15). Although a recent phase III
study evaluating everolimus as a second-line treatment for
advanced HCC after sorafenib failure resulted in negative
results (24), our data indicated that the evaluation of mTOR-
activation status may be a key component in the successful
treatment of HCCs using the mTOR inhibitor anthracimycin.
Further preclinical studies are required to evaluate the
efficacy of anthracimycin treatment of HCC.
Since mTOR inhibition resulted in alteration of metabolic
programs and protein synthesis in various types of cells, an
mTOR inhibitor, everolimus, is known to suppress the
neointimal hyperplasia of coronary arteries (25), angiogenesis
in the tumor (26, 27) as well as immune responses (28, 29).
Although we confirmed the suppression of mTOR signaling in
HCC cell lines, it is still unclear if anthracimycin also
suppresses the angiogenesis or immune responses, as observed
by everolimus. Because the immune suppression may have a
risk to escape cancer cells from immune surveillance, if
anthracimycin has a limited effect on immune cells, it would
be a better natural compound to eradicate HCC by targeting
both CSCs and non-CSCs than everolimus (30). The effect of
anthracimycin on angiogenesis and immunosuppression should
be clarified in future in vivo studies.
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